Stock Market Analysis & Comment

Markets gained yesterday, but it was hardly convincing. The Russell 2000 is the best example as it posted its fourth day of doji/spinning top candlesticks - which post a net gain - but do so from...

For the past two decades, the S&P 500 has underperformed the Nasdaq as tech stocks have been all the rage.Growth and innovation have transformed our economy and kept those companies (and stocks)...

Chip stocks are facing a steep downturn amid slowing demand and growing U.S.-China rivalry The Philadelphia Semiconductor Index (SOX) is down about 36% for the year to date Texas Instruments is one of...

The bull case for TWLO stock seems easy to make at a four-year low But the business is facing real challenges — and management isn’t responding Longer-term, this can still work, but...

The broad selloff witnessed in the first nine months of 2022 appears to have stalled—at least for now U.S. midterm elections could give stocks another push in the upcoming months However,...

Drugmaker Merck's (NYSE:MRK) stock has outperformed its competitors year to date (ytd), rising 30.6%. Pfizer (NYSE:PFE), which I am bearish on, is down 16.9% so far this year. The Rahway, New...

Stocks finished the day higher on Monday, following on from Friday’s rally. Yields were higher across the board, and the dollar was again weaker. Still, the S&P was able to generate a 1ish%...

In my last update on the S&P 500, using the Elliott Wave Principle (EWP), I found: “SPX 3886.75 remains the dividing line in the sand. If the S&P 500 manages to rally above that level...

An 80% rally from June lows raises fundamental concerns around HOOD Rising interest rates and lower costs could get the company to profitability From here, however, investors are relying on management...

November has been the best month of the year for U.S. stocks counting since 1950 AII investor sentiment has improved—although it remains below the historical average However, 2022 keeps adding...

Pfizer (NYSE:PFE) faces a $16 to $18 billion loss in revenue from 2025 through 2030 as it loses essential patents on five drugs.The drugs account for 40% of the company's Q3 revenue when its COVID...

Share repurchases might be on increase as firms pivot from a new tax in 2023 Management teams appear to be accelerating stock buybacks PKW ETF offers exposure to value and cyclical stocks while...

It is a big week, with the CPI report on Thursday and a bunch of government bond auctions later this week. That means rates will be on the move, and word that the China zero covid policy will remain...

Lyft is more vulnerable than its main rival, Uber, in a potential economic slowdown The biggest weakness that makes Lyft more exposed to economic shock is that it has failed to diversify during the...